Follow
Ashish M. Kamat, MD, MBBS, FACS
Ashish M. Kamat, MD, MBBS, FACS
Verified email at mdanderson.org
Title
Cited by
Cited by
Year
Bladder cancer
AM Kamat, NM Hahn, JA Efstathiou, SP Lerner, PU Malmström, W Choi, ...
The Lancet 388 (10061), 2796-2810, 2016
12862016
Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration
V Margulis, SF Shariat, SF Matin, AM Kamat, R Zigeuner, E Kikuchi, ...
Cancer 115 (6), 1224-1233, 2009
11292009
Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline
SS Chang, BH Bochner, R Chou, R Dreicer, AM Kamat, SP Lerner, ...
The Journal of urology 198 (3), 552-559, 2017
8922017
Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018
MGK Cumberbatch, I Jubber, PC Black, F Esperto, JD Figueroa, ...
European urology 74 (6), 784-795, 2018
7892018
CTLA-4 blockade increases IFNγ-producing CD4+ ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
CI Liakou, A Kamat, DN Tang, H Chen, J Sun, P Troncoso, C Logothetis, ...
Proceedings of the National Academy of Sciences 105 (39), 14987-14992, 2008
6192008
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial
BC Carthon, JD Wolchok, J Yuan, A Kamat, DS Ng Tang, J Sun, G Ku, ...
Clinical Cancer Research 16 (10), 2861-2871, 2010
5482010
Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer
DJ McConkey, W Choi, L Marquis, F Martin, MB Williams, J Shah, ...
Cancer and Metastasis Reviews 28, 335-344, 2009
4242009
Definitions, end points, and clinical trial designs for non–muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group
AM Kamat, RJ Sylvester, A Böhle, J Palou, DL Lamm, M Brausi, ...
Journal of Clinical Oncology 34 (16), 1935-1944, 2016
3632016
Focus on bladder cancer
CPN Dinney, DJ McConkey, RE Millikan, X Wu, M Bar-Eli, L Adam, ...
Cancer cell 6 (2), 111-116, 2004
3452004
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
AV Balar, AM Kamat, GS Kulkarni, EM Uchio, JL Boormans, M Roumiguié, ...
The Lancet Oncology 22 (7), 919-930, 2021
3272021
Repeat transurethral resection in non–muscle-invasive bladder cancer: a systematic review
MGK Cumberbatch, B Foerster, JWF Catto, AM Kamat, W Kassouf, ...
European urology 73 (6), 925-933, 2018
3152018
Micropapillary bladder cancer: a review of the University of Texas MD Anderson Cancer Center experience with 100 consecutive patients
AM Kamat, CPN Dinney, JR Gee, HB Grossman, AO Siefker‐Radtke, ...
Cancer 110 (1), 62-67, 2007
2962007
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
SA Boorjian, M Alemozaffar, BR Konety, ND Shore, LG Gomella, ...
The Lancet Oncology 22 (1), 107-117, 2021
2922021
ZKSCAN3 is a master transcriptional repressor of autophagy
S Chauhan, JG Goodwin, S Chauhan, G Manyam, J Wang, AM Kamat, ...
Molecular cell 50 (1), 16-28, 2013
2822013
ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers
AM Kamat, PK Hegarty, JR Gee, PE Clark, RS Svatek, N Hegarty, ...
European urology 63 (1), 4-15, 2013
2792013
A prognostic gene expression signature in the molecular classification of chemotherapy-naive urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy …
DJ McConkey, W Choi, YU Shen, IL Lee, S Porten, SF Matin, AM Kamat, ...
European urology 69 (5), 855-862, 2016
2762016
An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer
GS Kulkarni, OW Hakenberg, JE Gschwend, G Thalmann, W Kassouf, ...
European urology 57 (1), 60-70, 2010
2542010
Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort
HM Fritsche, M Burger, RS Svatek, C Jeldres, PI Karakiewicz, G Novara, ...
European urology 57 (2), 300-309, 2010
2532010
The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma
AM Kamat, JR Gee, CPN Dinney, HB Grossman, DA Swanson, ...
The Journal of urology 175 (3), 881-885, 2006
2512006
Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high‐risk upper tract transitional cell carcinoma
SF Matin, V Margulis, A Kamat, CG Wood, HB Grossman, GA Brown, ...
Cancer 116 (13), 3127-3134, 2010
2452010
The system can't perform the operation now. Try again later.
Articles 1–20